Manufacturing, Cell Therapies

There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.

A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.

For cell and gene therapies to reach their full potential, changes in manufacturing must be explored.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Finding specific solutions to overcome uncertainty has led to the evolution of a new clinical trial research environment.

Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.

Precompetitive consortiums seek solutions to industry-wide challenges.

AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Some progress has been made, but improvements are needed when harvesting cells for cell therapies.

The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.

BioPharm International spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors.

Thermo Fisher Scientific’s new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing.